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Tbjective: Growth factor and cell-based angiogenesis are attractive therapeutic
ptions for diabetic patients with end-stage coronary disease. Reduced collateral
essel formation observed in diabetes is associated with increased expression of
nti-angiogenic proteins, angiostatin and endostatin. The aim of this study was to
etermine the effects of insulin treatment on the diabetic angiogenic response to
hronic myocardial ischemia.
ethods: Yucatan miniswine were treated with alloxan (pancreatic -cell specific
oxin, 150 mg/kg) and divided into two groups. In the diabetic group (DM, n  8),
lood glucose levels were kept greater than 250 mg/dL, and in the insulin-treated
roup (IDM, n  6), intramuscular insulin was administered daily to keep blood
lucose less than 150 mg/dL. A third group of age-matched swine served as
ondiabetic controls (ND; n  8). Eight weeks later, all animals underwent
ircumflex artery ameroid constrictor placement to induce chronic ischemia. Myo-
ardial perfusion was assessed at 3 and 7 weeks after ameroid placement using
icrospheres. Microvascular function, capillary density, and myocardial expression
f anti-angiogenic mediators were evaluated.
esults: Diabetic animals exhibited significant impairments in endothelium-depen-
ent microvessel relaxation to adenosine diphosphate and substance P, which were
eversed in insulin-treated animals. Collateral-dependent perfusion in the ischemic
ircumflex territory, which was profoundly reduced in diabetic animals (0.18 
.02 vs 0.23  0.07 mL · min1 · g1; P  .001), improved significantly with
nsulin treatment (0.12  0.05 mL · min1 · g1; P  .01). Myocardial expression
f anti-angiogenic proteins, angiostatin and endostatin, showing a 4.3- and 3.6-fold
ncrease in diabetic animals respectively (both P  .01 vs ND), was markedly
educed in insulin-treated animals (2.3- and 1.8-fold vs ND; both P  .01).
onclusions: Insulin treatment successfully reversed diabetic coronary endothelial
ysfunction and significantly improved the endogenous angiogenic response. These
ro-angiogenic effects may be mediated through downregulation of anti-angiogenic
ediators. Insulin therapy appears to be a promising modality to enhance the
ngiogenic response in diabetic patients.
or more than a decade, cardiovascular researchers and clinicians have ex-
plored therapeutic angiogenesis, using growth factors or cell-based therapies,
as a treatment option for patients with coronary artery disease. Despite early
uccess in animal models, clinical trials of angiogenic therapies have yielded
isappointing results.1,2 One of the proposed explanations for the discorda
etween animal studies and clinical trials is the presence of various anti-angiogenic
nfluences that are found in patients with coronary artery disease but are absent in
oung healthy animals in which the majority of preclinical experiments are con-
ucted. These include, among others, diabetes, hypercholesterolemia, advanced age,
he Journal of Thoracic and Cardiovascular Surgery ● Volume 134, Number 6 1453
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CSPnd endothelial dysfunction. We have previously demon-
trated that diet-induced hypercholesterolemia is associated
ith endothelial dysfunction as well as an impairment in the
ndogenous3 and growth factor–induced angiogenic r-
ponse.4,5 Advanced age has been associated with impai
rowth factor signaling in patients with coronary artery
isease.6
Diabetes is a commonly found comorbid condition in
atients with coronary artery disease and is increasing in
revalence worldwide.7 Its presence is associated with ac-
elerated atherosclerosis as well as an impaired angiogenic
esponse to chronic ischemia, which has been demonstrated
n patients, both angiographically8 and in autopsy studies9
lthough therapeutic angiogenesis appears to be an attrac-
ive treatment option in patients with diabetes, the evalua-
ion of therapeutic modalities in the presence of diabetes is
imited, in large part, by the lack of a large animal model of
iabetes and chronic ischemia that can be used to evaluate
linically relevant end points. We10 have recently reported
he creation and thorough validation of such a model of
lloxan-induced diabetes in Yucatan miniswine. In this
odel, diabetes is induced with alloxan, a pancreatic -cell
pecific toxin. We demonstrated that a 15-week exposure to
hronic hypoinsulinemic hyperglycemia (type I diabetes)
as associated with many of the functional, microvascular,
nd molecular abnormalities associated with human diabe-
es, including endothelial dysfunction, impaired collateral-
ependent myocardial perfusion, and alterations in the an-
iogenic signaling in the myocardium. In this study, we
ought to determine the effects of glycemic control using
arenteral insulin treatment on microvascular function and
he endogenous angiogenic response to chronic myocardial
schemia.
aterials and Methods
eneral Experimental Sequence and Diabetes
nduction
wenty-two Yucatan miniswine of male sex (Sinclair Research
nc, Colombia, Mo) were used for the studies. Diabetes was
nduced when animals were 8 months old by a single intravenous
njection of alloxan (150 mg/kg). Only animals that achieved and
Abbreviations and Acronyms
ADP  adenosine 5’-diphosphate
Ang-1  angiopoiten-1
DM  diabetes group
dP/dt  first derivative of left ventricular pressure
IDM  insulin-treated diabetes group
ND  no diabetes control group
VEGF vascular endothelial growth factoraintained blood glucose levels greater than 200 mg/dL were m
454 The Journal of Thoracic and Cardiovascular Surgery ● Decncluded in the diabetes group. Animals were fed ad libitum and no
ietary modification was used. These animals were divided into
wo groups. In the diabetic group (DM, n 8), fasting blood sugar
as maintained between 250 and 400 mg/dL. In the insulin-treated
roup (IDM, n 6), glycemic control was achieved (fasting blood
ugar  150 mg/dL) through daily intramuscular insulin (70%
morphous, 30% crystalline) administration. Fasting blood glucose
as monitored every 2 days early after diabetes induction and 1 to
times per week thereafter by obtaining a small blood sample (50
L) from a capillary bed in the ear. Diabetes was maintained for
weeks before surgical instrumentation. Age-matched miniswine
ND, n  8) served as controls.
All animals underwent an identical experimental protocol in-
olving three separate procedures on each animal. Anesthesia was
erformed as reported previously,3 and animals received human
are in compliance with the Harvard Medical Area Institutional
nimal Care and Use Committee and the National Research Coun-
il’s “Guide for the Care and Use of Laboratory Animals,” pre-
ared by the Institute of Laboratory Animals and published by the
ational Institutes of Health (NIH publication No.5377-3, 1996).
n brief, for all surgical procedures, anesthesia was induced with
etamine (10 mg/kg intramuscularly), thiopental (5-10 mg/kg in-
ravenously), and thiopental 2.5% and maintained with a gas
ixture of oxygen at 1.5 to 2 L/min and isoflurane at 0.75% to
.0%. The animals were intubated and mechanically ventilated at
2 to 20 breaths/min.
The first procedure, performed via a small left anterolateral
horacotomy 8 weeks after diabetes induction, consisted of the
lacement of a 1.75-mm ameroid constrictor around the proximal
ircumflex artery and the injection of 1.5  107 gold-labeled
icrospheres into the left atrium during temporary occlusion of the
ircumflex coronary artery, to subsequently allow for identifica-
ion, by shadow labeling, of the myocardial territory at risk.
The second procedure, also performed via left anterolateral
horacotomy, 3 weeks after ameroid placement, consisted of 1.5 
07 lutetium microspheres injected in the left atrium during rest
onditions and 1.5  107 europium microspheres injected during
apid atrial pacing (150 beats/min) to allow for determination of
aseline perfusion after ameroid closure. To document ameroid
losure, we performed left coronary angiography through an 8F
heath (Cordis Corporation, Miami, Fla) surgically inserted in the
emoral artery, using a catheter with the appropriate distal angu-
ation and high atomic weight contrast (Mallinckrodt Inc, St Louis,
o).
The third procedure was carried out 4 weeks after the second
rocedure and 7 weeks after ameroid placement. Sternotomy was
erformed, 1.5  107 samarium microspheres were injected into
he left atrium during rest conditions, and 1.5  107 lanthanum
icrospheres were injected during pacing (150 beats/min). The
nimals were then humanely killed with 10 mL/kg of a saturated
Cl solution administered intravenously. Cardiac samples were
arvested and snap frozen for molecular studies, sectioned,
eighed, and dried for myocardial microsphere analyses, and put
n 4°C Krebs solution for in vitro assessment of coronary micro-
ascular reactivity. Ameroid constrictors were resected along with
segment of circumflex artery and examined under low-power
agnification to confirm occlusion.
ember 2007
I
R
A
d
l
f
e y.
T
e
m
(
v
t
a
b
a
a
v
l
A
M
i
m

e
i
m
c
g
c
b
S
r
s
a
c
f
a
n
g
p
d
l
C
A
A
B
t
u
t
w
d

t
c
I
M
d
a
s
w
e
4
t
W
W
d
t
1
P
5
r
p
c
e
(
s
1
o
C
a
a
i
G
c
B
D
D
e
w
e
t
g
b
w
w
B
a
t
R
E
D
Boodhwani et al Cardiopulmonary Support and Physiology
CS
Pn Vitro Assessment of Coronary Microvessel
eactivity
fter cardiac harvest, epicardial coronary arterioles (80-150 m in
iameter and 1-2 mm in length) originating from branches of the
eft anterior descending and circumflex arteries were dissected
rom the surrounding tissue with a 40 dissecting microscope and
xamined in isolated organ chambers, as described previousl11
he responses to sodium nitroprusside (1 nmol-100 mol), an
ndothelium-independent cyclic guanosine monophosphate–
ediated vasodilator, as well as adenosine 5=-diphosphate (ADP)
1 nmol/L–10 mol/L), substance P (1 fmol/L–1 nmol/L), and
ascular endothelial growth factor (VEGF, 1 fmol/L–1 nmol/L),
hree endothelium-dependent receptor-mediated vasodilators that
ct via bioavailable nitric oxide, were studied after precontraction
y 20% to 50% of the baseline diameter with the thromboxane A2
nalog U46619 (0.1-1 mol/L). Relaxation responses were defined
s the percent relaxation of the precontracted diameter, and 6 to 8
essels were examined from 6 to 8 animals in each group from the
eft anterior descending and the circumflex territories.
ssessment of Myocardial Perfusion
yocardial perfusion was assessed during each procedure with
sotope-labeled microspheres (BioPAL, Worcester, Mass) using
ethods previously reported.3 Isotope-labeled microspheres, 15
m in diameter, of different isotopic mass were used at each
xperimental stage. Gold-labeled microspheres were injected dur-
ng temporary circumflex occlusion at the time of ameroid place-
ent to identify myocardial samples that originated from the
ircumflex coronary distribution (those with the lowest count of
old-labeled microspheres). Lutetium- and europium-labeled mi-
rospheres were used during the second procedure to determine
aseline blood flow at rest and with atrial pacing at 150 beats/min.
amarium- and lanthanum-labeled microspheres were injected at
est and during pacing during the third procedure. Reference blood
amples were obtained from the femoral artery during the second
nd third procedures. After the animals were humanely killed, 10
ircumferential, transmural left ventricular sections were collected
or assay of isotope-labeled microspheres in each animal, weighed,
nd dried at 60°C for 24 hours. Each sample was exposed to
eutron beams and microsphere densities were measured in a
amma counter. Adjusted myocardial blood flow (at rest and with
acing), reflecting changes in lateral myocardial perfusion, was
etermined from the two myocardial samples that showed the
owest count of gold microspheres by the following equations:
rude blood flow (tissue sample) 
(Withdrawal rate [mL ⁄ min] ⁄ weight [tissue sample])
 (Isotope counts [tissue sample] ⁄
Isotope counts [reference blood sample])
djusted blood flow  Crude blood flow (third operation)
 Crude blood flow at baseline (second operation)
ssessment of Myocardial Function
efore tissue harvest, a catheter was surgically inserted through
he femoral artery, passed into the left ventricle, and left ventric-
lar pressure was recorded over 10-second intervals. Global sys-
olic and diastolic function was determined with Cardiosoft soft- 1
The Journal of Thoracicare (Sonosoft Inc, London, Ontario, Canada) by taking the first
erivative of left ventricular pressure (dP/dt). Next, maximum
dP/dt (systolic function) and minimum dP/dt (diastolic func-
ion) measurements were obtained and averaged over 15 to 20
ardiac cycles in each animal.
mmunohistochemistry
yocardial sections from the circumflex territory of control and
iabetic animals were stained with anti-platelet–endothelial cell
dhesion molecule-1 (CD-31) antibody diluted to 1:600 (BD Bio-
ciences, San Diego, Calif) as previously described.3 The sections
ere counterstained with methyl green and examined for capillary
ndothelial cell density in a triplicate, blinded fashion from 600 
40 m (0.264 mm2) cross-sectional fields randomly selected from
he center of circumflex territories.
estern Blotting
hole-cell lysates were isolated from the homogenized myocar-
ial samples with a radioimmunoprecipitation assay buffer (Bos-
on Bioproducts, Worcester, Mass) and centrifuged at 12,000g for
0 minutes at 4°C to separate soluble from insoluble fractions.
rotein concentration was measured spectrophotometrically at a
95-nm wavelength with a DC protein assay kit (Bio-Rad Labo-
atories, Hercules, Calif). Forty to eighty micrograms of total
rotein were fractionated by 4% to 20% gradient, sodium dode-
ylsulfate polyacrylamide gel electrophoresis (Invitrogen, San Di-
go, Calif) and transferred to polyvinyl difluoride membranes
Millipore, Bedford, Mass). Each membrane was incubated with
pecific antibodies as follows: anti-VEGF antibody (dilution
:250) (Calbiochem, San Diego, Calif), anti–endothelial nitric
xide synthase antibody (1:2500) (BD Biosciences, San Jose,
alif), anti-Tie-2 antibody (1:200) (Santa Cruz, Santa Cruz, Calif),
nti-endostatin antibody (1:1000) (Upstate, Chicago, Ill), and anti-
ngiostatin antibody. Then the membranes were incubated for 1 hour
n diluted appropriate secondary antibody (Jackson Immunolab, West
rove, Pa). Immune complexes were visualized with the enhanced
hemiluminescence detection system (Amersham, Piscataway, NJ).
ands were quantified by densitometry of radioautograph films.
ata Analysis
ata are reported as means  SEM. Microvessel responses are
xpressed as percent relaxation of the preconstricted diameter and
ere analyzed by 2-way repeated measures analysis of variance,
xamining the relationship between vessel relaxation, log concen-
ration of the vasoactive agent of interest, and the experimental
roup (SAS version 9.1; SAS Institute, Inc, Cary, NC). Immuno-
lots are expressed as a ratio of protein to loading band density and
ere analyzed after digitization and quantification of x-ray films
ith ImageJ 1.33 (National Institutes of Health, Bethesda, Md).
lots and isotope-labeled microsphere data were analyzed by
nalyses of variance. Bonferroni corrections were applied to mul-
iple tests.
esults
xperimental Model
iabetes induction was attempted in 17 animals, of which
4 (82%) demonstrated consistent blood glucose levels
and Cardiovascular Surgery ● Volume 134, Number 6 1455
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CSPreater than 200 mg/dL. One animal died of renal failure
nd 2 failed to become hyperglycemic. Four animals in the
M group occasionally required low doses of insulin (10-20
/day) to keep blood sugar levels less than 400 mg/dL. In
he IDM group, all animals required large doses of daily
nsulin (average dose of 78 U/day) to achieve target fasting
lood glucose levels. Three of the 6 IDM animals required
wice a day dosing to achieve adequate glycemic control.
ypoglycemic episodes requiring treatment occurred in 2
nimals on 4 occasions. Fasting blood glucose levels in the
ifferent groups throughout the experimental protocol are
epicted in Figure 1. All animals survived the entire e
mental protocol.
oronary Microvessel Reactivity
esults of microvessel relaxation studies are summarized in
igure 2. U46619 was used at a dose of 1  106 mol/L to
reconstrict coronary microvessels by an average of 40% 
% of the baseline diameter. Compared with the control
roup (ND), diabetic animals (DM and IDM) demonstrated
n impairment in microvessel relaxation to endothelium-
ependent vasorelaxants, ADP and substance P (both P 
igure 1. Blood glucose levels in no diabetes (ND), diabetes
DM), and insulin-treated diabetes (IDM) groups over the 7-week
xperimental protocol.456 The Journal of Thoracic and Cardiovascular Surgery ● Dec-
001), in the ischemic territory, suggesting reduced nitric
xide bioavailability. IDM animals showed almost com-
lete recovery of this endothelial dysfunction. Furthermore,
icrovessel relaxation in response to VEGF was markedly
mpaired in diabetic animals (P .001). IDM animals dem-
nstrated significant improvement in the microvascular re-
ponse to VEGF compared with the DM group (P  .01)
ut still remained impaired compared with controls (P 
05). Endothelium-independent relaxation, in response to
odium nitroprusside, was not significantly different be-
ween groups (P  .09).
yocardial Perfusion
rude circumflex territory myocardial blood flow was sim-
lar between control, DM, and IDM groups at 3 weeks after
meroid placement, both at rest (0.43  0.07, 0.33  0.02,
nd 0.34  0.04 mL · min1 · g1, respectively; P  .10)
nd with pacing (0.30 0.04 vs 0.39 0.03 vs 0.28 0.08
L · min1 · g1; P .25). At 7 weeks, the control animals
ad an increase in circumflex territory perfusion at rest
0.23  0.07 mL · min1 · g1), whereas the DM animals
emonstrated a reduction in perfusion (0.18  0.02 mL ·
in1 · g1; P  .001). Insulin-treated diabetic animals
IDM) demonstrated significantly improved perfusion com-
ared with DM animals (0.12  0.05 mL · min1 · g1; P
.001) but remained significantly lower than control ani-
als (P  .05). These differences were also evident during
apid atrial pacing (Figure 3).
yocardial Function
lobal left ventricular function was measured at the time of
he final procedure, 7 weeks after ameroid placement, and
ystolic and diastolic function were quantified using maxi-
um positive dP/dt and minimum negative dP/dt, respec-
ively. Diabetic animals demonstrated reduced left ventric-
lar contractility (P  .001), which was significantly
Figure 2. Coronary microvascular reactivity. Per-
cent relaxation to increasing concentrations of
vasodilating agents after preconstriction with
U46619. Responses to endothelium-dependent
vasodilators ADP (A), Substance P (B), and VEGF
(C), as well as endothelium-independent vasodi-
lator SNP (D) in the ischemic territory of ND (n
8), DM (n  8), and IDM (n  6) animals. ADP,
Adenosine 5= diphosphate; SNP, sodium nitro-
prusside; VEGF, vascular endothelial growth fac-
tor. *P < .001 vs ND. **P < .01 vs DM. †P < .05
vs controls. ND, DM, and IDM as in Figure 1.ember 2007
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Pmproved with insulin treatment (P  .01). Similar abnor-
alities were observed with respect to diastolic function in
iabetic animals (P  .05). However, insulin treatment did
ot result in a statistically significant difference (Figure
apillary Endothelial Cell Density
igure 5 shows the density of CD31 capillary endothelial
ells (cells/high power field) in the ischemic territory of pigs
rom all groups 7 weeks after ameroid placement. Diabetic
nimals had significantly reduced endothelial cell density
ompared with controls (160 10 vs. 263 18; P .001).
es were used to determine baseline-adjusted circum-
) and diabetic swine (DM, n  8; IDM, n  6) after
ry perfusion, which was profoundly reduced in DM
lin treatment, but still remained lower than controls.
, DM, and IDM as in Figure 1.
igure 5. Endothelial cell density. CD31 endothelial cell density
er high power field (0.264 mm2) was determined in the ischemic
erritory of control (n  8) and diabetic (DM, n  8; IDM, n  6)
nimals. Diabetic animals had reduced endothelial cell density
ompared with controls, which was significantly improved in
nsulin-treated diabetic animals. *P < .001 vs ND. **P < .001 vsFigure 3. Myocardial perfusion. Isotope-labeled microspher
flex territory myocardial blood perfusion in control (n  8
circumflex ameroid occlusion. Adjusted circumflex territo
animals at rest (A) and with pacing (B), improved with insu
*P < .001 vs ND. **P < .001 vs DM and P < .05 vs ND. NDigure 4. Left ventricular (LV) function. Diabetic animals demon-
trated reduced LV contractility and impaired LV relaxation. In-
ulin treatment resulted in significant improvement in LV systolic
unction (n  4-6/group; *P < .001 vs ND; **P < .01 vs DM; †P <M. ND, DM, and IDM as in Figure 1.
and Cardiovascular Surgery ● Volume 134, Number 6 1457
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CSP nimals in the IDM group demonstrated significantly
igher endothelial cell density than did DM animals (230 
; P  .001 vs DM).
estern Blotting
e10 have previously reported the effects of diabetes on
xpression and activity of angiogenic mediators in the myo-
ardium. We examined the effects of insulin treatment on
ro-angiogenic and anti-angiogenic mediator expression in
he diabetic myocardium.
Anti-angiogenic mediators: Angiostatin and endostatin.
igure 6 displays the results of Western blots of 
ngiogenic mediators, angiostatin and endostatin. The ex-
ression of both angiostatin (4.1  1.3-fold; P  .01) and
ndostatin (3.6  0.4-fold; P  .01) was profoundly in-
reased in the myocardium of diabetic animals. IDM ani-
als demonstrated a significant reduction in myocardial
ngiostatin (1.8  0.2-fold vs ND; P  .05 for comparison
f IDM vs DM) and endostatin (2.3  0.2-fold vs ND; P 
01 for comparison of IDM vs DM) expression. Similar
atterns of expression of the anti-angiogenic proteins were
bserved in both the ischemic circumflex and the nonisch-
mic territories of the left anterior descending coronary
rtery.
Pro-angiogenic mediators: VEGF and angiopoietin
athways. VEGF and angiopoiten-1 (Ang-1) are important
ro-angiogenic growth factors that mediate their effects
hrough binding to their respective receptors, VEGFR2 and
ie-2. The DM group had significantly lower myocardial
xpression of growth factors, VEGF and Ang-1 (0.60 
.11-fold and 0.62  0.06-fold vs ND, respectively; both P
.05). Insulin treatment in the IDM animals led to signif-
cant increases in VEGF and Ang-1 levels compared with
he DM group (1.17  0.08-fold and 1.03  0.08-fold vs
D, respectively; both P  .05 vs DM). VEGFR2 levels
ere similar in all groups. Tie-2 expression was similar
etween ND and DM animals but significantly increased in
DM animals (2.3 0.2-fold vs ND; P  .001). Expression
f downstream mediator endothelial nitric oxide synthase
as similar between groups (Figure 7). <
458 The Journal of Thoracic and Cardiovascular Surgery ● Dec-
iscussion
n a clinically relevant model of diabetes and chronic myo-
ardial ischemia, we sought to evaluate the effects of gly-
emic control using insulin on the endogenous angiogenic
esponse. We found that insulin treatment was successful in
chieving the target fasting blood glucose level of less than
50 mg/dL and associated with reversal of the endothelial
ysfunction observed in diabetic animals. VEGF signaling
Figure 6. Myocardial expression of anti-
angiogenic mediators. Expression of
angiostatin (A) and endostatin (B) was
significantly increased in the myocar-
dium of diabetic animals and was sig-
nificantly reduced in insulin-treated di-
abetic animals. (n  4-6/group). *P <
.01. **P < .05. ND, DM, and IDM as in
Figure 1.
igure 7. Myocardial expression of pro-angiogenic mediators. A,
xpression of growth factors, VEGF and Ang-1, their respective
eceptors, VEGFR2 and Tie-2, as well as downstream mediator
NOS were assessed. B, Quantitative analysis showed that dia-
etic animals had reduced myocardial expression of VEGF and
ng-1, but VEGFR2 and Tie-2 expression was unchanged. Insulin
reatment caused an increase in VEGF and Ang-1 expression as
ell as a significant increase in Tie-2 expression. Ang-1, Angio-
oiten-1; VEGF, vascular endothelial growth factor; eNOS, endo-
helial nitric oxide synthase (n  4-6/group). *P < .05 v. ND. **P
 .05 vs DM; †P < .001 vs ND. ND, DM, and IDM as in Figure 1.
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Pn coronary microvessels, which was significantly impaired
n diabetic animals, recovered only partially with insulin
reatment. Perfusion of the collateral dependent territory
as profoundly diminished in diabetic animals. Insulin
reatment led to a significant improvement but did not
ormalize the perfusion of the ischemic myocardium. This
as corroborated by the morphologic evidence of improved
ndothelial cell density in insulin-treated animals and was
lso associated with improvement in global left ventricular
ystolic function. Exploration of pro-angiogenic and anti-
ngiogenic pathways revealed that the profound increases in
he expression of anti-angiogenic proteins, angiostatin and
ndostatin, observed with diabetes, were significantly re-
uced in insulin-treated animals. Furthermore, the expres-
ion of pro-angiogenic growth factors, VEGF and Ang-1, as
ell as the receptor Tie-2, was enhanced with insulin treat-
ent. In summary, this study provides functional, morpho-
ogic, microvascular, and molecular evidence for the pro-
ngiogenic effects of glycemic control achieved with insulin
reatment in the setting of diabetes.
Glycemic control remains the mainstay of treatment in
iabetes and has been shown to improve both macrovascu-
ar and microvascular complications of diabetes.12,13 Insulin
reatment, with or without oral hypoglycemic agents, is the
ost common method used clinically to achieve glycemic
ontrol. Insulin has multifaceted effects on the myocardium,
hich mainly involve the regulation of fuel consumption,
lucose transport, glycogen synthesis, and glycolysis14
ore relevant to vascular function, however, is the demon-
trated ability of insulin to increase endothelial nitric oxide
vailability in the vasculature.15 Furthermore, the insulin
eceptor, which is present in the myocardium, is a tyrosine
inase receptor that shares many of the downstream medi-
tors common to angiogenic growth factors and their recep-
ors, for example PI3 kinase and mitogen-activated protein
inases.15 In addition to its direct effects on the myocard
nd coronary vasculature, insulin exerts indirect effects
hrough the reduction in systemic blood glucose levels. By
educing blood glucose levels, insulin can avoid the adverse
ffects of chronic hyperglycemia, which include increased
xidative stress, chronic inflammation, and the nonenzy-
atic glycation of proteins, particularly in the extracellular
atrix.16,17 The pro-angiogenic effects of insulin demo-
trated in this study may be due to a combination of the
forementioned processes.
We found that although endothelium-independent mi-
rovessel relaxation to sodium nitroprusside was preserved
n all groups, diabetes was associated with impaired micro-
ascular response to ADP and substance P, implying endo-
helial dysfunction and reduced nitric oxide bioavailability.
reatment with insulin led to a complete reversal in this
ndothelial dysfunction. However, the impairment in
EGF-induced microvessel relaxation, observed in diabe- d
The Journal of Thoracices, was only partially improved in insulin-treated animals,
uggesting a persistent, residual impairment in VEGF sig-
aling in the coronary microvasculature. Examination of
ro-angiogenic proteins at the molecular level revealed that
xpression of VEGF, Ang-1, and its receptor, Tie-2, was
arkedly enhanced with insulin treatment.
Angiostatin and endostatin, cleavage products of plas-
inogen and collagen XVIII, respectively, have been
hown to have potent anti-angiogenic effects in vitro and in
odent models.18,19 Weihrauch and associates20 have asso-
iated increased angiostatin with hyperglycemia and im-
aired angiogenesis in dogs. The association between an-
iostatin and diabetes and diminished coronary collateral
ormation has also been shown in patients with coronary
isease.21,22 We10 have previously shown that both a-
iostatin and endostatin are upregulated many fold in the
etting of diabetes. In this study, we found that insulin
reatment caused a significant reduction but not complete
ormalization in angiostatin and endostatin expression. The
xpression of these anti-angiogenic mediators mirrored the
unctional finding of significantly improved but not normal-
zed perfusion of the ischemic circumflex territory. These
bservations provide further evidence for the critical role of
hese anti-angiogenic mediators, both as markers and as
otential novel targets for the modulation of the angiogenic
esponse in diabetes. Furthermore, the effects of insulin on
atrix metalloproteinases, which are responsible for the
roduction of these anti-angiogenic proteins, needs to be
urther evaluated in this setting.
odel Strengths and Limitations
ur model of alloxan-induced diabetes largely mimics type
diabetes, that is, hypoinsulinemic hyperglycemia. Al-
hough various pathophysiologic and molecular aspects of
he disease are common between type I and type II diabe-
es,23 including chronic hyperglycemia, endothelial dy-
unction, increased oxidative stress and inflammation, ac-
elerated atherosclerosis, and diminished angiogenesis,
ther features may be different and may limit the general-
zability of this model to type II diabetes and insulin resis-
ance. Last, whereas this model of chronic ischemia pro-
ides physiologically relevant measures of perfusion as well
s morphologic assessment of angiogenesis, it is limited by
he fact that molecular markers are only assessed at a single
ime point, 7 weeks after ameroid placement, and therefore,
cute changes in pro-angiogenic and anti-angiogenic medi-
tors may not be completely captured in this model.
onclusions
nsulin treatment, targeted to achieve glycemic control,
everses coronary endothelial dysfunction and significantly
mproves but does not normalize the endogenous myocar-
ial angiogenic response to chronic ischemia in the setting
and Cardiovascular Surgery ● Volume 134, Number 6 1459
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1
CSPf diabetes. These effects may be mediated by the direct
ffects of insulin on the myocardium and coronary vascu-
ature or indirectly through systemic reductions in blood
lucose. Anti-angiogenic proteins, angiostatin and endosta-
in, are downregulated with insulin treatment and appear to
lay an important role in the diabetic angiogenic response.
nsulin therapy appears to be a promising strategy to im-
rove the results of growth factor or cell-based angiogenic
herapies in diabetic patients.
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iscussion
r Mark J. Krasna (Towson, Md). I was quite impressed with the
echnical feat of this study. Can you elaborate on the three proce-
ures that you performed on each of these animals and was there
ny mortality among the three groups?
Dr Boodhwani. In the past we have done more than 400
meroid constrictor experiments in our laboratory. We found that
n a potent model of diet induced hypercholesteremia, there was
bout a 10% to 20% mortality rate with the animals, but over time
he techniques have been improved and we have a much better
ense of what the model entails now. Fortunately, in this study, we
id not lose any animals.
Dr Krasna. Along the same lines, when you are doing three
rocedures on each animal, was there a significant infection rate
rom the first to the third, or was that also low?
Dr. Boodhwani. In the normal, nondiabetic animals (group
D) there was virtually no infection. In the diabetic animals we
ound that there was some impairment of wound healing and
reakdown of the incision. However, to emphasize, all animals
ere treated with postoperative antibiotics for 5 days.
Dr Paul W. M. Fedak (Calgary, Alberta, Canada). This is a
reat study. I think this model is going to be very important for
uture studies in the area. My question to you is, I did not see
nything about regional or global left ventricular function. Was
hat addressed in this study or will it be addressed in any future
tudies? If not, what would you hypothesize would be the effects
f insulin treatment?
Dr Boodhwani. In the past we have demonstrated that circum-
ex ameroid constrictor placement leads to a reduction in perfu-
ion as well as regional wall motion abnormalities. Regional wall
otion abnormalities were not specifically studied in this model,
lthough we did assess global left ventricular function. We expect,
hough, that improvement in perfusion would likely result inDiabetes-induced oxidative stress and low-grade inflammation in por-
cine coronary arteries. Circulation. 2003;108:472-8. improvement in regional wall motion as well.ember 2007
